SANIONA AB (PUBL) (30S) - Net Assets
Based on the latest financial reports, SANIONA AB (PUBL) (30S) has net assets worth €635.16 Million EUR (≈ $742.57 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€679.74 Million ≈ $794.69 Million USD) and total liabilities (€44.58 Million ≈ $52.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of SANIONA AB (PUBL) for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €635.16 Million |
| % of Total Assets | 93.44% |
| Annual Growth Rate | 22.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 136.8 |
SANIONA AB (PUBL) - Net Assets Trend (2021–2025)
This chart illustrates how SANIONA AB (PUBL)'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of SANIONA AB (PUBL) for the complete picture of this company's asset base.
Annual Net Assets for SANIONA AB (PUBL) (2021–2025)
The table below shows the annual net assets of SANIONA AB (PUBL) from 2021 to 2025. For live valuation and market cap data, see market value of SANIONA AB (PUBL).
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €635.16 Million ≈ $742.57 Million |
+173.99% |
| 2024-12-31 | €231.82 Million ≈ $271.02 Million |
+1156.60% |
| 2023-12-31 | €-21.94 Million ≈ $-25.65 Million |
-141.63% |
| 2022-12-31 | €52.71 Million ≈ $61.62 Million |
-81.31% |
| 2021-12-31 | €282.00 Million ≈ $329.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SANIONA AB (PUBL)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 25638700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €987.70 Million | 155.50% |
| Total Equity | €635.16 Million | 100.00% |
SANIONA AB (PUBL) Competitors by Market Cap
The table below lists competitors of SANIONA AB (PUBL) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CTT Systems AB
ST:CTT
|
$170.65 Million |
|
Chia Chang Co Ltd
TW:4942
|
$170.67 Million |
|
Chime Ball Technology Co Ltd
TWO:1595
|
$170.72 Million |
|
Landmark Bancorp Inc
NASDAQ:LARK
|
$170.73 Million |
|
TrueBlue Inc
NYSE:TBI
|
$170.57 Million |
|
Heungkuk F&M I
KO:000540
|
$170.44 Million |
|
Sonadezi Chau Duc Shareholding Co
VN:SZC
|
$170.28 Million |
|
1911 Gold Corp
V:AUMB
|
$170.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SANIONA AB (PUBL)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 231,818,000 to 635,159,000, a change of 403,341,000 (174.0%).
- Net income of 284,666,000 contributed positively to equity growth.
- New share issuances of 114,951,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €284.67 Million | +44.82% |
| Share Issuances | €114.95 Million | +18.1% |
| Other Changes | €3.72 Million | +0.59% |
| Total Change | €- | 173.99% |
Book Value vs Market Value Analysis
This analysis compares SANIONA AB (PUBL)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.82 | €1.22 | x |
| 2022-12-31 | €0.71 | €1.22 | x |
| 2023-12-31 | €-0.29 | €1.22 | x |
| 2024-12-31 | €2.06 | €1.22 | x |
| 2025-12-31 | €4.60 | €1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SANIONA AB (PUBL) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 44.82%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 65.53%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.07x
- Recent ROE (44.82%) is above the historical average (-84.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -145.71% | -3921.53% | 0.02x | 1.56x | €-439.10 Million |
| 2022 | -401.40% | -1384.34% | 0.10x | 2.92x | €-216.84 Million |
| 2023 | 0.00% | -568.94% | 0.26x | 0.00x | €-93.62 Million |
| 2024 | 81.40% | 56.39% | 0.99x | 1.47x | €165.52 Million |
| 2025 | 44.82% | 65.53% | 0.64x | 1.07x | €221.15 Million |
Industry Comparison
This section compares SANIONA AB (PUBL)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $353,958,690
- Average return on equity (ROE) among peers: -34.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SANIONA AB (PUBL) (30S) | €635.16 Million | -145.71% | 0.07x | $170.61 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $204.16 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more